Neon Therapeutics, Inc. Common Stock
NTGN
NTGN was delisted on the 5th of May, 2020.
58 hedge funds and large institutions have $28.4M invested in Neon Therapeutics, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 20 increasing their positions, 10 reducing their positions, and 9 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 10
89% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 9
14% more funds holding
Funds holding: 51 → 58 (+7)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
69% less capital invested
Capital invested by funds: $90.2M → $28.4M (-$61.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FIA
FNY Investment Advisers
New York
|
+$639K |
| 2 |
MA
MYDA Advisors
Woodmere,
New York
|
+$472K |
| 3 |
Renaissance Technologies
New York
|
+$428K |
| 4 |
BlackRock
New York
|
+$421K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$403K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$7.09M |
| 2 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$3.33M |
| 3 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
-$3M |
| 4 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$829K |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$578K |
NTGN Hedge Fund Activity: Q3 2019 in Review
58 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Neon Therapeutics, Inc. Common Stock (NTGN) for Q3 2019, worth a combined $28.4M — down 69% from $90.2M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new NTGN positions and 9 closed out — a net gain of 8 holders — while 20 added to existing stakes and 10 trimmed.
The largest buyer was FNY Investment Advisers, opening a new position worth an estimated $639K. The largest seller was Wellington Management Group, exiting entirely with an estimated $7.09M sold.
- 58 institutional investors held Neon Therapeutics, Inc. Common Stock (NTGN) as of Q3 2019, up from 51 in Q2 2019.
- Funds reported $28.4M of Neon Therapeutics, Inc. Common Stock stock for Q3 2019, down 69% quarter-over-quarter.
- 17 funds opened new Neon Therapeutics, Inc. Common Stock positions in Q3 2019 and 9 closed out, a net change of +8 holders.
- The largest Neon Therapeutics, Inc. Common Stock buyer in Q3 2019 was FNY Investment Advisers, an estimated $639K added.
- The largest Neon Therapeutics, Inc. Common Stock seller in Q3 2019 was Wellington Management Group, an estimated $7.09M sold.
Based on aggregated 13F filings for Q3 2019.